Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery

Advanced Drug Delivery Reviews

Volumn 102, Issue , 2016, Pages 33-54

  O'Connor, Gemma ^a,b   Gleeson, Laura E ^b   Fagan Murphy, Aidan ^a,d   Cryan, Sally Ann ^a,c,d   O'Sullivan, Mary P ^b   Keane, Joseph ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Adjunctive therapy; Ant tubercular; Immunomodulation; Inhalation; Particle engineering; Pre clinical testing; Targeted drug delivery; Vitamin

Indexed keywords

DRUG DELIVERY; MEDICINE; VITAMINS;

ADJUNCTIVE THERAPY; ANT-TUBERCULAR; IMMUNO MODULATIONS; INHALATION; PARTICLE ENGINEERING; PRE-CLINICAL TESTING; TARGETED DRUG DELIVERY;

PATIENT TREATMENT;

2 CHLORO 5 NITROBENZANILIDE; ALPHA TOCOPHEROL; ASCORBIC ACID; CORTICOSTEROID DERIVATIVE; FLUOXETINE; GEFITINIB; ICOSANOID; LIPID; MATRIX METALLOPROTEINASE INHIBITOR; METFORMIN; MICRORNA; NANOPARTICLE; PROTEIN KINASE INHIBITOR; PYRIDOXINE; RAPAMYCIN; RETINOL; ROSIGLITAZONE; TELMISARTAN; TUBERCULOSTATIC AGENT; VITAMIN D; ZILEUTON;

AUTOPHAGY; BACTERIAL STRAIN; DENDRITIC CELL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG THERAPY; ENGINEERING; HOST DIRECTED THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; INHALER; LUNG ALVEOLUS EPITHELIUM CELL; LUNG TUBERCULOSIS; MACROPHAGE; METABOLIC REGULATION; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; THREE DIMENSIONAL IMAGING; TUBERCULOSIS CONTROL; DRUG INDUSTRY; MULTIMODALITY CANCER THERAPY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; HUMANS; TUBERCULOSIS;

EID: 84971617620     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.024     Document Type: Review

References (307)

1. WHO Global Tuberculosis Report 2015.
2. Daniel T.M. The history of tuberculosis. Respir. Med. 2006, 100:1862-1870.
3. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10:621-629.
4. Lei X., Liu Q., Escobar E., Philogene J., Zhu H., Wang Y., Tang S. Public-private mix for tuberculosis care and control: a systematic review. Int. J. Infect. Dis. 2015, 34:20-32.
5. TBAlliance Our mission 2015.
6. Bloemberg G.V., Keller P.M., Stucki D., Trauner A., Borrell S., Latshang T., Coscolla M., Rothe T., Homke R., Ritter C., Feldmann J., Schulthess B., Gagneux S., Bottger E.C. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N. Engl. J. Med. 2015, 373:1986-1988.
7. Hawn T.R., Shah J.A., Kalman D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 2015, 264:344-362.
8. Wallis R.S., Hafner R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 2015, 15:255-263.
9. Kaufmann S.H., Lange C., Rao M., Balaji K.N., Lotze M., Schito M., Zumla A.I., Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir. Med. 2014, 2:301-320.
10. Oprea T.I., Bauman J.E., Bologa C.G., Buranda T., Chigaev A., Edwards B.S., Jarvik J.W., Gresham H.D., Haynes M.K., Hjelle B., Hromas R., Hudson L., Mackenzie D.A., Muller C.Y., Reed J.C., Simons P.C., Smagley Y., Strouse J., Surviladze Z., Thompson T., Ursu O., Waller A., Wandinger-Ness A., Winter S.S., Wu Y., Young S.M., Larson R.S., Willman C., Sklar L.A. Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg. 2011, 8:61-69.
11. Payen M.C., De Wit S., Martin C., Sergysels R., Muylle I., Van Laethem Y., Clumeck N. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16:558-560.
12. Roca F.J., Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013, 153:521-534.
13. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., Ko D.C., Zou Y., Bang N.D., Chau T.T., Vary J.C., Hawn T.R., Dunstan S.J., Farrar J.J., Thwaites G.E., King M.C., Serhan C.N., Ramakrishnan L. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
14. Guler R., Brombacher F. Host-directed drug therapy for tuberculosis. Nat. Chem. Biol. 2015, 11:748-751.
15. Olaru I.D., Lange C., Heyckendorf J. Personalized medicine for patients with MDR-TB. J. Antimicrob. Chemother. 2016, 71(4):852-855.
16. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 2001, 48:431-434.
17. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32:140-150.
18. Hirota K., Hasegawa T., Nakajima T., Inagawa H., Kohchi C., Soma G., Makino K., Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 2010, 142:339-346.
19. Maretti E., Rossi T., Bondi M., Croce M.A., Hanuskova M., Leo E., Sacchetti F., Iannuccelli V. Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis. Int. J. Pharm. 2014, 462:74-82.
20. Verma R.K., Kaur J., Kumar K., Yadav A.B., Misra A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 2008, 52:3195-3201.
21. Verma R.K., Agrawal A.K., Singh A.K., Mohan M., Gupta A., Gupta P., Gupta U.D., Misra A. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2013, 93:412-417.
22. de Faria T.J., Roman M., de Souza N.M., De Vecchi R., de Assis J.V., dos Santos A.L., Bechtold I.H., Winter N., Soares M.J., Silva L.P., De Almeida M.V., Bafica A. An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob. Agents Chemother. 2012, 56:2259-2267.
23. Chan J.G., Chan H.K., Prestidge C.A., Denman J.A., Young P.M., Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur. J. Pharm. Biopharm. 2013, 83:285-292.
24. Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 2013, 57:2613-2619.
25. Lawlor C., O'Sullivan M.P., Rice B., Dillon P., Gallagher P.J., O'Leary S., Shoyele S., Keane J., Cryan S.A. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J. Mater. Sci. Mater. Med. 2012, 23:89-98.
26. Hertel S.P., Winter G., Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv. Drug Deliv. Rev. 2015, 93:79-94.
27. Kiran D., Podell B.K., Chambers M., Basaraba R.J. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin. Immunopathol. 2016, 38(2):167-183.
28. Formulary B.N. Tuberculosis 2016, The Pharmaceutical Press.
29. WHO Treatment of Tuberculosis Guidelines 2010.
30. Gunther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin. Med. (Lond.) 2014, 14:279-285.
31. Lonnroth K., Williams B.G., Cegielski P., Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int. J. Epidemiol. 2010, 39:149-155.
32. WHO Nutritional Care and Support for Patients with Tuberculosis 2013.
33. Lange N.E., Sparrow D., Vokonas P., Litonjua A.A. Vitamin D deficiency, smoking, and lung function in the Normative Aging Study. Am. J. Respir. Crit. Care Med. 2012, 186:616-621.
34. Padayatty S.J., Katz A., Wang Y., Eck P., Kwon O., Lee J.H., Chen S., Corpe C., Dutta A., Dutta S.K., Levine M. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J. Am. Coll. Nutr. 2003, 22:18-35.
35. O'Leary S.M., Coleman M.M., Chew W.M., Morrow C., McLaughlin A.M., Gleeson L.E., O'Sullivan M.P., Keane J. Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 2014, 190:1430-1436.
36. Crowle A.J., Ross E.J. Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 1989, 57:840-844.
37. Semba R.D. Vitamin A as "anti-infective" therapy, 1920-1940. J. Nutr. 1999, 129:783-791.
38. Martindale: The Complete Drug Reference Tretinoin 2015, The Pharmaceutical Press.
39. Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 2008, 8:685-698.
40. Greenstein R.J., Su L., Brown S.T. Vitamins A & D inhibit the growth of mycobacteria in radiometric culture. PLoS One 2012, 7.
41. Greenstein R.J., Su L., Shahidi A., Brown W.D., Clifford A., Brown S.T. Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and vitamins A and D: clinical implications. Int. J. Infect. Dis. 2014, 26:37-43.
42. Yamada H., Mizuno S., Ross A.C., Sugawara I. Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis. J. Nutr. 2007, 137:2696-2700.
43. Estrella J.L., Kan-Sutton C., Gong X., Rajagopalan M., Lewis D.E., Hunter R.L., Eissa N.T., Jagannath C. A novel in vitro human macrophage model to study the persistence of Mycobacterium tuberculosis using vitamin D(3) and retinoic acid activated THP-1 macrophages. Front. Microbiol. 2011, 2:67.
44. Anand P.K., Kaul D. Vitamin D3-dependent pathway regulates TACO gene transcription. Biochem. Biophys. Res. Commun. 2003, 310:876-877.
45. Anand P.K., Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol. Lett. 2005, 250:137-144.
46. Anand P.K., Kaul D., Sharma M. Synergistic action of vitamin D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria. J. Microbiol. Immunol. Infect. 2008, 41:17-25.
47. Pandey A.K., Sassetti C.M. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4376-4380.
48. Wheelwright M., Kim E.W., Inkeles M.S., De Leon A., Pellegrini M., Krutzik S.R., Liu P.T. All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2. J. Immunol. 2014, 192:2280-2290.
49. Rodriguez G.M. Control of iron metabolism in Mycobacterium tuberculosis. Trends Microbiol. 2006, 14:320-327.
50. da Cunha M.S., Siqueira E.M., Trindade L.S., Arruda S.F. Vitamin A deficiency modulates iron metabolism via ineffective erythropoiesis. J. Nutr. Biochem. 2014, 25:1035-1044.
51. Coleman M.M., Ruane D., Moran B., Dunne P.J., Keane J., Mills K.H. Alveolar macrophages contribute to respiratory tolerance by inducing FoxP3 expression in naive T cells. Am. J. Respir. Cell Mol. Biol. 2013, 48:773-780.
52. Sanchez D., Rojas M., Hernandez I., Radzioch D., Garcia L.F., Barrera L.F. Role of TLR2- and TLR4-mediated signaling in Mycobacterium tuberculosis-induced macrophage death. Cell. Immunol. 2010, 260:128-136.
53. Liu P.T., Krutzik S.R., Kim J., Modlin R.L. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J. Immunol. 2005, 174:2467-2470.
54. Arts R.J., Blok B.A., van Crevel R., Joosten L.A., Aaby P., Benn C.S., Netea M.G. Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes. J. Leukoc. Biol. 2015, 98:129-136.
55. Beckenbach L., Baron J.M., Merk H.F., Loffler H., Amann P.M. Retinoid treatment of skin diseases. Eur. J. Dermatol. 2015, 25:384-391.
56. Bushue N., Wan Y.J. Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev. 2010, 62:1285-1298.
57. Massaro G.D., Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. 1997, 3:675-677.
58. Kumarguru B.N., Natarajan M., Biligi D.S., Raghupathi A.R. Giant cell lesions of lungs: a histopathological and morphometric study of seven autopsy cases. J. Clin. Diagn. Res. 2015, 9:EC12-EC16.
59. Miranda M.S., Breiman A., Allain S., Deknuydt F., Altare F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?. Int. J. Immunol. Res. 2012, 2012.
60. Ulrichs T., Kaufmann S.H. New insights into the function of granulomas in human tuberculosis. J. Pathol. 2006, 208:261-269.
61. Tsai M.C., Chakravarty S., Zhu G., Xu J., Tanaka K., Koch C., Tufariello J., Flynn J., Chan J. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 2006, 8:218-232.
62. Visser M.E., Grewal H.M., Swart E.C., Dhansay M.A., Walzl G., Swanevelder S., Lombard C., Maartens G. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am. J. Clin. Nutr. 2011, 93:93-100.
63. Lawson L., Thacher T.D., Yassin M.A., Onuoha N.A., Usman A., Emenyonu N.E., Shenkin A., Davies P.D., Cuevas L.E. Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis. Tropical Med. Int. Health 2010, 15:1481-1490.
64. Leyssens C., Verlinden L., Verstuyf A. The future of vitamin D analogs. Front. Physiol. 2014, 5:122.
65. Crowle A.J., Ross E.J., May M.H. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 1987, 55:2945-2950.
66. Rook G.A., Steele J., Fraher L., Barker S., Karmali R., O'Riordan J., Stanford J. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986, 57:159-163.
67. Liu P.T., Stenger S., Tang D.H., Modlin R.L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007, 179:2060-2063.
68. Agier J., Efenberger M., Brzezinska-Blaszczyk E. Cathelicidin impact on inflammatory cells. Cent. Eur. J. Immunol. 2015, 40:225-235.
69. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., Ochoa M.T., Schauber J., Wu K., Meinken C., Kamen D.L., Wagner M., Bals R., Steinmeyer A., Zugel U., Gallo R.L., Eisenberg D., Hewison M., Hollis B.W., Adams J.S., Bloom B.R., Modlin R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
70. Salamon H., Bruiners N., Lakehal K., Shi L., Ravi J., Yamaguchi K.D., Pine R., Gennaro M.L. Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J. Immunol. 2014, 193:30-34.
71. Leaf D.E., Croy H.E., Abrahams S.J., Raed A., Waikar S.S. Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit. Care 2015, 19:80.
72. Mily A., Rekha R.S., Kamal S.M., Arifuzzaman A.S., Rahim Z., Khan L., Haq M.A., Zaman K., Bergman P., Brighenti S., Gudmundsson G.H., Agerberth B., Raqib R. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One 2015, 10.
73. Daley P., Jagannathan V., John K.R., Sarojini J., Latha A., Vieth R., Suzana S., Jeyaseelan L., Christopher D.J., Smieja M., Mathai D. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 2015, 15:528-534.
74. Martineau A.R., Timms P.M., Bothamley G.H., Hanifa Y., Islam K., Claxton A.P., Packe G.E., Moore-Gillon J.C., Darmalingam M., Davidson R.N., Milburn H.J., Baker L.V., Barker R.D., Woodward N.J., Venton T.R., Barnes K.E., Mullett C.J., Coussens A.K., Rutterford C.M., Mein C.A., Davies G.R., Wilkinson R.J., Nikolayevskyy V., Drobniewski F.A., Eldridge S.M., Griffiths C.J. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011, 377:242-250.
75. Salahuddin N., Ali F., Hasan Z., Rao N., Aqeel M., Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. BMC Infect. Dis. 2013, 13:22.
76. Zasloff M. Fighting infections with vitamin D. Nat. Med. 2006, 12:388-390.
77. Snider D.E. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980, 61:191-196.
78. Dalvi S.M., Patil V.W., Ramraje N.N., Phadtare J.M., Gujarathi S.U. Nitric oxide, carbonyl protein, lipid peroxidation and correlation between antioxidant vitamins in different categories of pulmonary and extra pulmonary tuberculosis. Malays. J. Med. Sci. 2013, 20:21-30.
79. Taneja N.K., Dhingra S., Mittal A., Naresh M., Tyagi J.S. Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C. PLoS One 2010, 5.
80. Vilcheze C., Hartman T., Weinrick B., Jacobs W.R. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat. Commun. 2013, 4:1881.
81. Estevinho B.N., Carlan I., Blaga A., Rocha F. Soluble vitamins (vitamin B12 and vitamin C) microencapsulated with different biopolymers by a spray drying process. Powder Technol. 2016, 289:71-78.
82. British National Formulary Interactions 2015, The Pharmaceutical Press.
83. Deretic V., Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009, 5:527-549.
84. Gutierrez M.G., Master S.S., Singh S.B., Taylor G.A., Colombo M.I., Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766.
85. Levine B., Mizushima N., Virgin H.W. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
86. Bradfute S.B., Castillo E.F., Arko-Mensah J., Chauhan S., Jiang S., Mandell M., Deretic V. Autophagy as an immune effector against tuberculosis. Curr. Opin. Microbiol. 2013, 16:355-365.
87. Armstrong J.A., Hart P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 1971, 134:713-740.
88. Clemens D.L., Horwitz M.A. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 1995, 181:257-270.
89. Vergne I., Chua J., Singh S.B., Deretic V. Cell biology of mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 2004, 20:367-394.
90. Vergne I., Singh S., Roberts E., Kyei G., Master S., Harris J., de Haro S., Naylor J., Davis A., Delgado M., Deretic V. Autophagy in immune defense against Mycobacterium tuberculosis. Autophagy 2006, 2:175-178.
91. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
92. Coriat R., Mir O., Ropert S., Loulergue P., Billemont B., Goldwasser F. Reactivation of tuberculosis during temsirolimus therapy. Investig. New Drugs 2011, 29:1494-1496.
93. Fijalkowska-Morawska J.B., Jagodzinska M., Nowicki M. Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. Ann. Transplant. 2011, 16:107-110.
94. Lin C.C., Wang J.Y., Pu Y.S. Active tuberculosis during temsirolimus and bevacizumab treatment. J. Clin. Oncol. 2013, 31:e18-e20.
95. Jagannath C., Lindsey D.R., Dhandayuthapani S., Xu Y., Hunter R.L., Eissa N.T. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med. 2009, 15:267-276.
96. Gupta A., Pant G., Mitra K., Madan J., Chourasia M.K., Misra A. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol. Pharm. 2014, 11:1201-1207.
97. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 2012, 11:709-730.
98. Stanley S.A., Barczak A.K., Silvis M.R., Luo S.S., Sogi K., Vokes M., Bray M.A., Carpenter A.E., Moore C.B., Siddiqi N., Rubin E.J., Hung D.T. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 2014, 10.
99. Schiebler M., Brown K.H., Newton K.S., Renna M., Hepburn L., Klapholz C., Coulter S., Obregón-Henao A., Henao Tamayo M., Basaraba R., Kampmann B., Henry K., Burgon J., Renshaw S., Fleming A., Kay R., Anderson K., Hawkins P., Ordway D., Rubinsztein D., Floto R. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol. Med. 2015, 7:127-139.
100. Shoji-Kawata S., Sumpter R., Leveno M., Campbell G.R., Zou Z., Kinch L., Wilkins A.D., Sun Q., Pallauf K., MacDuff D., Huerta C., Virgin H.W., Helms J.B., Eerland R., Tooze S.A., Xavier R., Lenschow D.J., Yamamoto A., King D., Lichtarge O., Grishin N.V., Spector S.A., Kaloyanova D.V., Levine B. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013, 494:201-206.
101. Singhal A., Jie L., Kumar P., Hong G.S., Leow M.K., Paleja B., Tsenova L., Kurepina N., Chen J., Zolezzi F., Kreiswirth B., Poidinger M., Chee C., Kaplan G., Wang Y.T., De Libero G. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 2014, 6. (263ra159).
102. Kelly B., Tannahill G.M., Murphy M.P., O'Neill L.A. Metformin inhibits the production of reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of interleukin-1beta (IL-1beta) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J. Biol. Chem. 2015, 290:20348-20359.
103. Vashisht R., Brahmachari S.K. Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis. J. Transl. Med. 2015, 13:83.
104. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
105. Parihar S.P., Guler R., Khutlang R., Lang D.M., Hurdayal R., Mhlanga M.M., Suzuki H., Marais A.D., Brombacher F. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 2014, 209:754-763.
106. Liappis A.P., Kan V.L., Rochester C.G., Simon G.L. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis. 2001, 33:1352-1357.
107. Kang Y.A., Choi N.K., Seong J.M., Heo E.Y., Koo B.K., Hwang S.S., Park B.J., Yim J.J., Lee C.H. The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. Int. J. Tuberc. Lung Dis. 2014, 18:717-724.
108. Almeida P.E., Silva A.R., Maya-Monteiro C.M., Torocsik D., D'Avila H., Dezso B., Magalhaes K.G., Castro-Faria-Neto H.C., Nagy L., Bozza P.T. Mycobacterium bovis bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. J. Immunol. 2009, 183:1337-1345.
109. Rajaram M.V., Brooks M.N., Morris J.D., Torrelles J.B., Azad A.K., Schlesinger L.S. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J. Immunol. 2010, 185:929-942.
110. Ballesteros I., Cuartero M.I., Pradillo J.M., de la Parra J., Perez-Ruiz A., Corbi A., Ricote M., Hamilton J.A., Sobrado M., Vivancos J., Nombela F., Lizasoain I., Moro M.A. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARgamma and 5-LO-dependent pathways. J. Leukoc. Biol. 2014, 95:587-598.
111. McGettrick A.F., O'Neill L.A. How metabolism generates signals during innate immunity and inflammation. J. Biol. Chem. 2013, 288:22893-22898.
112. Palsson-McDermott E.M., O'Neill L.A. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 2013, 35:965-973.
113. Brown G.D., Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003, 19:311-315.
114. Cheng S.C., Quintin J., Cramer R.A., Shepardson K.M., Saeed S., Kumar V., Giamarellos-Bourboulis E.J., Martens J.H., Rao N.A., Aghajanirefah A., Manjeri G.R., Li Y., Ifrim D.C., Arts R.J., van der Veer B.M., Deen P.M., Logie C., O'Neill L.A., Willems P., van de Veerdonk F.L., van der Meer J.W., Ng A., Joosten L.A., Wijmenga C., Stunnenberg H.G., Xavier R.J., Netea M.G. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014, 345:1250684.
115. Rosentul D.C., Plantinga T.S., Oosting M., Scott W.K., Velez Edwards D.R., Smith P.B., Alexander B.D., Yang J.C., Laird G.M., Joosten L.A., van der Meer J.W., Perfect J.R., Kullberg B.J., Netea M.G., Johnson M.D. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J. Infect. Dis. 2011, 204:1138-1145.
116. Willment J.A., Gordon S., Brown G.D. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J. Biol. Chem. 2001, 276:43818-43823.
117. Mayer-Barber K.D., Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol. Rev. 2015, 264:264-275.
118. Behar S.M., Divangahi M., Remold H.G. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?. Nat. Rev. Microbiol. 2010, 8:668-674.
119. Chen M., Divangahi M., Gan H., Shin D.S., Hong S., Lee D.M., Serhan C.N., Behar S.M., Remold H.G. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 2008, 205:2791-2801.
120. Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., Fortune S., Behar S.M., Remold H.G. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 2009, 10:899-906.
121. Bafica A., Scanga C.A., Serhan C., Machado F., White S., Sher A., Aliberti J. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 2005, 115:1601-1606.
122. Rangel Moreno J., Estrada Garcia I., De La Luz Garcia Hernandez M., Leon D.A., Marquez R., Hernandez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 2002, 106:257-266.
123. Tobin D.M., Vary J.C., Ray J.P., Walsh G.S., Dunstan S.J., Bang N.D., Hagge D.A., Khadge S., King M.C., Hawn T.R., Moens C.B., Ramakrishnan L. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
124. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., Derrick S.C., Shi R., Kumar N.P., Wei W., Yuan X., Zhang G., Cai Y., Babu S., Catalfamo M., Salazar A.M., Via L.E., Barry C.E., Sher A. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
125. Vilaplana C., Marzo E., Tapia G., Diaz J., Garcia V., Cardona P.J. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 2013, 208:199-202.
126. Dutta N.K., Kumar K.A., Mazumdar K., Dastidar S.G. In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium. Indian J. Exp. Biol. 2004, 42:922-927.
127. Dutta N.K., Mazumdar K., Dastidar S.G., Park J.H. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int. J. Antimicrob. Agents 2007, 30:336-340.
128. Dooley D.P., Carpenter J.L., Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin. Infect. Dis. 1997, 25:872-887.
129. Critchley J.A., Young F., Orton L., Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2013, 13:223-237.
130. Mayanja-Kizza H., Jones-Lopez E., Okwera A., Wallis R.S., Ellner J.J., Mugerwa R.D., Whalen C.C. C. Uganda-Case Western Research, Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J. Infect. Dis. 2005, 191:856-865.
131. Lighvani A.A., Frucht D.M., Jankovic D., Yamane H., Aliberti J., Hissong B.D., Nguyen B.V., Gadina M., Sher A., Paul W.E., O'Shea J.J. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15137-15142.
132. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 1993, 178:2249-2254.
133. Saito S., Nakano M. Nitric oxide production by peritoneal macrophages of Mycobacterium bovis BCG-infected or non-infected mice: regulatory role of T lymphocytes and cytokines. J. Leukoc. Biol. 1996, 59:908-915.
134. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease The International Chronic Granulomatous Disease Cooperative Study Group. N. Engl. J. Med. 1991, 324:509-516.
135. Key L.L., Rodriguiz R.M., Willi S.M., Wright N.M., Hatcher H.C., Eyre D.R., Cure J.K., Griffin P.P., Ries W.L. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N. Engl. J. Med. 1995, 332:1594-1599.
136. Seyer L., Greeley N., Foerster D., Strawser C., Gelbard S., Dong Y., Schadt K., Cotticelli M.G., Brocht A., Farmer J., Wilson R.B., Lynch D.R. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol. Scand. 2015, 132:7-15.
137. Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., Brauns C., Weiden M., Hoshino Y., Bateman E., Rom W.N. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One 2009, 4.
138. Gao X.F., Yang Z.W., Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Infect. Dis. 2011, 15:e594-e600.
139. Koh W.J., Kwon O.J., Suh G.Y., Chung M.P., Kim H., Lee N.Y., Kim T.S., Lee K.S. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci. 2004, 19:167-171.
140. Suarez-Mendez R., Garcia-Garcia I., Fernandez-Olivera N., Valdes-Quintana M., Milanes-Virelles M.T., Carbonell D., Machado-Molina D., Valenzuela-Silva C.M., Lopez-Saura P.A. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 2004, 4:44.
141. Condos R., Rom W.N., Schluger N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349:1513-1515.
142. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 1998, 70:83-243.
143. Greinert U., Ernst M., Schlaak M., Entzian P. Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur. Respir. J. 2001, 17:1049-1051.
144. de Beaucoudrey L., Samarina A., Bustamante J., Cobat A., Boisson-Dupuis S., Feinberg J., Al-Muhsen S., Janniere L., Rose Y., de Suremain M., Kong X.F., Filipe-Santos O., Chapgier A., Picard C., Fischer A., Dogu F., Ikinciogullari A., Tanir G., Al-Hajjar S., Al-Jumaah S., Frayha H.H., AlSum Z., Al-Ajaji S., Alangari A., Al-Ghonaium A., Adimi P., Mansouri D., Ben-Mustapha I., Yancoski J., Garty B.Z., Rodriguez-Gallego C., Caragol I., Kutukculer N., Kumararatne D.S., Patel S., Doffinger R., Exley A., Jeppsson O., Reichenbach J., Nadal D., Boyko Y., Pietrucha B., Anderson S., Levin M., Schandene L., Schepers K., Efira A., Mascart F., Matsuoka M., Sakai T., Siegrist C.A., Frecerova K., Bluetters-Sawatzki R., Bernhoft J., Freihorst J., Baumann U., Richter D., Haerynck F., De Baets F., Novelli V., Lammas D., Vermylen C., Tuerlinckx D., Nieuwhof C., Pac M., Haas W.H., Muller-Fleckenstein I., Fleckenstein B., Levy J., Raj R., Cohen A.C., Lewis D.B., Holland S.M., Yang K.D., Wang X., Wang X., Jiang L., Yang X., Zhu C., Xie Y., Lee P.P., Chan K.W., Chen T.X., Castro G., Natera I., Codoceo A., King A., Bezrodnik L., Di Giovani D., Gaillard M.I., de Moraes-Vasconcelos D., Grumach A.S., da Silva Duarte A.J., Aldana R., Espinosa-Rosales F.J., Bejaoui M., Bousfiha A.A., Baghdadi J.E., Ozbek N., Aksu G., Keser M., Somer A., Hatipoglu N., Aydogmus C., Asilsoy S., Camcioglu Y., Gulle S., Ozgur T.T., Ozen M., Oleastro M., Bernasconi A., Mamishi S., Parvaneh N., Rosenzweig S., Barbouche R., Pedraza S., Lau Y.L., Ehlayel M.S., Fieschi C., Abel L., Sanal O., Casanova J.L. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010, 89:381-402.
145. Ni Cheallaigh C., Sheedy F.J., Harris J., Munoz-Wolf N., Lee J., West K., McDermott E.P., Smyth A., Gleeson L.E., Coleman M., Martinez N., Hearnden C.H., Tynan G.A., Carroll E.C., Jones S.A., Corr S.C., Bernard N.J., Hughes M.M., Corcoran S.E., O'Sullivan M., Fallon C.M., Kornfeld H., Golenbock D., Gordon S.V., O'Neill L.A., Lavelle E.C., Keane J. A common variant in the adaptor Mal regulates interferon gamma signaling. Immunity 2016, 44:368-379.
146. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., Frodsham A.J., Walley A.J., Kyrieleis O., Khan A., Aucan C., Segal S., Moore C.E., Knox K., Campbell S.J., Lienhardt C., Scott A., Aaby P., Sow O.Y., Grignani R.T., Sillah J., Sirugo G., Peshu N., Williams T.N., Maitland K., Davies R.J., Kwiatkowski D.P., Day N.P., Yala D., Crook D.W., Marsh K., Berkley J.A., O'Neill L.A., Hill A.V. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat. Genet. 2007, 39:523-528.
147. Toossi Z., Kleinhenz M.E., Ellner J.J. Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis. J. Exp. Med. 1986, 163:1162-1172.
148. Johnson J.L., Ssekasanvu E., Okwera A., Mayanja H., Hirsch C.S., Nakibali J.G., Jankus D.D., Eisenach K.D., Boom W.H., Ellner J.J., Mugerwa R.D. C. Uganda-Case Western Reserve University Research, Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 168:185-191.
149. Shen H., Min R., Tan Q., Xie W., Wang H., Pan H., Zhang L., Xu H., Zhang X., Dai J. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch. Med. Sci. 2015, 11:584-590.
150. Johnson B.J., Ress S.R., Willcox P., Pati B.P., Lorgat F., Stead P., Saha R., Lukey P., Laochumroonvorapong P., Corral L., et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol. Ther. 1995, 1:185-196.
151. Johnson B., Bekker L.G., Ress S., Kaplan G. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. Novartis Found. Symp. 1998, 217:99-106. (discussion 106-111).
152. Geffner L., Yokobori N., Basile J., Schierloh P., Balboa L., Romero M.M., Ritacco V., Vescovo M., Gonzalez Montaner P., Lopez B., Barrera L., Aleman M., Abatte E., Sasiain M.C., de la Barrera S. Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains. Infect. Immun. 2009, 77:5025-5034.
153. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345:1098-1104.
154. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 2006, 194:486-492.
155. Blackmore T.K., Manning L., Taylor W.J., Wallis R.S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin. Infect. Dis. 2008, 47:e83-e85.
156. Jorge J.H., Graciela C., Pablo A.P., Luis S.H. A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis. J. Clin. Rheumatol. 2012, 18:189-191.
157. Wallis R.S., van Vuuren C., Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin. Infect. Dis. 2009, 48:1429-1432.
158. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 1991, 173:699-703.
159. Fu L.M., Fu-Liu C.S. Thalidomide and tuberculosis. Int. J. Tuberc. Lung Dis. 2002, 6:569-572.
160. Schoeman J.F., Fieggen G., Seller N., Mendelson M., Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J. Child Neurol. 2006, 21:301-308.
161. Schoeman J.F., Andronikou S., Stefan D.C., Freeman N., van Toorn R. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J. Child Neurol. 2010, 25:822-828.
162. Kamath S., Vaccaro S.A., Rea T.H., Ochoa M.T. Recognizing and managing the immunologic reactions in leprosy. J. Am. Acad. Dermatol. 2014, 71:795-803.
163. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 1993, 177:1675-1680.
164. Haslett P.A., Roche P., Butlin C.R., Macdonald M., Shrestha N., Manandhar R., Lemaster J., Hawksworth R., Shah M., Lubinsky A.S., Albert M., Worley J., Kaplan G. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J. Infect. Dis. 2005, 192:2045-2053.
165. Schoeman J.F., Springer P., van Rensburg A.J., Swanevelder S., Hanekom W.A., Haslett P.A., Kaplan G. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J. Child Neurol. 2004, 19:250-257.
166. Koo M.S., Manca C., Yang G., O'Brien P., Sung N., Tsenova L., Subbian S., Fallows D., Muller G., Ehrt S., Kaplan G. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 2011, 6.
167. Subbian S., Tsenova L., O'Brien P., Yang G., Koo M.S., Peixoto B., Fallows D., Dartois V., Muller G., Kaplan G. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 2011, 7.
168. Subbian S., Tsenova L., O'Brien P., Yang G., Koo M.S., Peixoto B., Fallows D., Zeldis J.B., Muller G., Kaplan G. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am. J. Pathol. 2011, 179:289-301.
169. Maiga M., Agarwal N., Ammerman N.C., Gupta R., Guo H., Maiga M.C., Lun S., Bishai W.R. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 2012, 7.
170. Maiga M., Ammerman N.C., Maiga M.C., Tounkara A., Siddiqui S., Polis M., Murphy R., Bishai W.R. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J. Infect. Dis. 2013, 208:512-519.
171. Ernst J.D. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 1998, 66:1277-1281.
172. Lebeis S.L., Kalman D. Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. Cell Host Microbe 2009, 5:114-122.
173. Druker B.J., Sawyers C.L., Capdeville R., Ford J.M., Baccarani M., Goldman J.M. Chronic myelogenous leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2001, 87-112.
174. Napier R.J., Rafi W., Cheruvu M., Powell K.R., Zaunbrecher M.A., Bornmann W., Salgame P., Shinnick T.M., Kalman D. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011, 10:475-485.
175. Bruns H., Stegelmann F., Fabri M., Dohner K., van Zandbergen G., Wagner M., Skinner M., Modlin R.L., Stenger S. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 2012, 189:4069-4078.
176. Napier R.J., Norris B.A., Swimm A., Giver C.R., Harris W.A., Laval J., Napier B.A., Patel G., Crump R., Peng Z., Bornmann W., Pulendran B., Buller R.M., Weiss D.S., Tirouvanziam R., Waller E.K., Kalman D. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog. 2015, 11.
177. Golub L.M., McNamara T.F., Ryan M.E., Kohut B., Blieden T., Payonk G., Sipos T., Baron H.J. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J. Clin. Periodontol. 2001, 28:146-156.
178. O'Kane C.M., Elkington P.T., Jones M.D., Caviedes L., Tovar M., Gilman R.H., Stamp G., Friedland J.S. STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis. Am. J. Respir. Cell Mol. Biol. 2010, 43:465-474.
179. Walker N.F., Clark S.O., Oni T., Andreu N., Tezera L., Singh S., Saraiva L., Pedersen B., Kelly D.L., Tree J.A., D'Armiento J.M., Meintjes G., Mauri F.A., Williams A., Wilkinson R.J., Friedland J.S., Elkington P.T. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 2012, 185:989-997.
180. Fol M., Druszczynska M., Wlodarczyk M., Ograczyk E., Rudnicka W. Immune response gene polymorphisms in tuberculosis. Acta Biochim. Pol. 2015, 62:633-640.
181. Baltimore D., Boldin M.P., O'Connell R.M., Rao D.S., Taganov K.D. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 2008, 9:839-845.
182. Iannaccone M., Dorhoi A., Kaufmann S.H. Host-directed therapy of tuberculosis: what is in it for microRNA?. Expert Opin. Ther. Targets 2014, 18:491-494.
183. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
184. Ueberberg B., Kohns M., Mayatepek E., Jacobsen M. Are microRNAs suitable biomarkers of immunity to tuberculosis?. Mol. Cell. Pediatr. 2014, 1:8.
185. Ren N., Gao G., Sun Y., Zhang L., Wang H., Hua W., Wan K., Li X. MicroRNA signatures from multidrugresistant Mycobacterium tuberculosis. Mol. Med. Rep. 2015, 12:6561-6567.
186. Xu Z., Zhou A., Ni J., Zhang Q., Wang Y., Lu J., Wu W., Karakousis P.C., Lu S., Yao Y. Differential expression of miRNAs and their relation to active tuberculosis. Tuberculosis (Edinb.) 2015, 95:395-403.
187. Kim J.K., Yuk J.M., Kim S.Y., Kim T.S., Jin H.S., Yang C.S., Jo E.K. MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection. J. Immunol. 2015, 194:5355-5365.
188. Kumar R., Sahu S.K., Kumar M., Jana K., Gupta P., Gupta U.D., Kundu M., Basu J. MicroRNA 17-5p regulates autophagy in Mycobacterium tuberculosis-infected macrophages by targeting Mcl-1 and STAT3. Cell. Microbiol. 2015.
189. Huang J., Jiao J., Xu W., Zhao H., Zhang C., Shi Y., Xiao Z. miR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol. Med. Rep. 2015, 12:7102-7108.
190. Xi X., Zhang C., Han W., Zhao H., Zhang H., Jiao J. MicroRNA-223 is upregulated in active tuberculosis patients and inhibits apoptosis of macrophages by targeting FOXO3. Genet. Test. Mol. Biomarkers 2015, 19:650-656.
191. Song Q., Li H., Shao H., Li C., Lu X. MicroRNA-365 in macrophages regulates Mycobacterium tuberculosis-induced active pulmonary tuberculosis via interleukin-6. Int. J. Clin. Exp. Med. 2015, 8:15458-15465.
192. Sanders M. Inhalation therapy: an historical review. Prim. Care Respir. J. 2007, 16:71-81.
193. Garcia Contreras L., Sung J., Ibrahim M., Elbert K., Edwards D., Hickey A. Pharmacokinetics of inhaled rifampicin porous particles for tuberculosis treatment: insight into rifampicin absorption from the lungs of guinea pigs. Mol. Pharm. 2015, 12:2642-2650.
194. Hickey A.J., Durham P.G., Dharmadhikari A., Nardell E.A. Inhaled drug treatment for tuberculosis: past progress and future prospects. J. Control. Release 2016, (in press). 10.1016/j.jconrel.2015.11.018.
195. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26:2401-2416.
196. Condos R., Hull F.P., Schluger N.W., Rom W.N., Smaldone G.C. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest 2004, 125:2146-2155.
197. Grahmann P.R., Braun R.K. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. Int. J. Tuberc. Lung Dis. 2008, 12:636-644.
198. Rosas-Taraco A.G., Higgins D.M., Sanchez-Campillo J., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 2009, 41:136-145.
199. Tulbah A.S., Ong H.X., Colombo P., Young P.M., Traini D. Novel simvastatin inhalation formulation and characterisation. AAPS PharmSciTech 2014, 15:956-962.
200. Jeong Y.I., Song J.G., Kang S.S., Ryu H.H., Lee Y.H., Choi C., Shin B.A., Kim K.K., Ahn K.Y., Jung S. Preparation of poly(dl-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int. J. Pharm. 2003, 259:79-91.
201. Cirpanli Y., Unlu N., Calis S., Hincal A.A. Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres. J. Microencapsul. 2005, 22:877-889.
202. Almouazen E., Bourgeois S., Boussaid A., Valot P., Malleval C., Fessi H., Nataf S., Briancon S. Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages. Int. J. Pharm. 2012, 430:207-215.
203. Desai T.R., Finlay W.H. Nebulization of niosomal all-trans-retinoic acid: an inexpensive alternative to conventional liposomes. Int. J. Pharm. 2002, 241:311-317.
204. Brooks A.D., Tong W., Benedetti F., Kaneda Y., Miller V., Warrell R.P. Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother. Pharmacol. 2000, 46:313-318.
205. Frankenberger M., Heimbeck I., Moller W., Mamidi S., Kassner G., Pukelsheim K., Wjst M., Neiswirth M., Kroneberg P., Lomas D., Halsall D., Iadarola P., Fertl A., Haussinger K., Ziegler-Heitbrock L. Inhaled all-trans retinoic acid in an individual with severe emphysema. Eur. Respir. J. 2009, 34:1487-1489.
206. Minko T., Stefanov A., Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J. Appl. Physiol. 1985, 93(2002):1550-1560. discussion 1549.
207. Alqahtani S., Simon L., Astete C.E., Alayoubi A., Sylvester P.W., Nazzal S., Shen Y., Xu Z., Kaddoumi A., Sabliov C.M. Cellular uptake, antioxidant and antiproliferative activity of entrapped alpha-tocopherol and gamma-tocotrienol in poly (lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi). J. Colloid Interface Sci. 2015, 445:243-251.
208. Hamahata A., Enkhbaatar P., Kraft E.R., Lange M., Leonard S.W., Traber M.G., Cox R.A., Schmalstieg F.C., Hawkins H.K., Whorton E.B., Horvath E.M., Szabo C., Traber L.D., Herndon D.N., Traber D.L. gamma-Tocopherol nebulization by a lipid aerosolization device improves pulmonary function in sheep with burn and smoke inhalation injury. Free Radic. Biol. Med. 2008, 45:425-433.
209. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb.) 2011, 91:71-81.
210. Geller D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care 2005, 50:1313-1321. discussion 1321-1312.
211. Saadat A., Zhu B., Haghi M., King G., Colombo G., Young P.M., Traini D. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. J. Pharm. Pharmacol. 2014, 66:639-645.
212. Zhu B., Haghi M., Goud M., Young P.M., Traini D. The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. Eur. J. Pharm. Sci. 2015, 76:68-72.
213. Miller D.P., Tan T., Tarara T.E., Nakamura J., Malcolmson R.J., Weers J.G. Physical characterization of tobramycin inhalation powder: I. Rational design of a stable engineered-particle formulation for delivery to the lungs. Mol. Pharm. 2015, 12:2582-2593.
214. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
215. Lawlor C., O'Sullivan M.P., Sivadas N., O'Leary S., Gallagher P.J., Keane J., Cryan S.A. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol. Pharm. 2011, 8:1100-1112.
216. Lawlor C., O'Connor G., O'Leary S., Gallagher P.J., Cryan S.A., Keane J., O'Sullivan M.P. Treatment of Mycobacterium tuberculosis-infected macrophages with poly(lactic-co-glycolic acid) microparticles drives NFkappab and autophagy dependent bacillary killing. PLoS One 2016, 11.
217. Sharma R., Yadav A.B., Muttil P., Kajal H., Misra A. Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis 2011, 91:107-110.
218. Hickey A.J., Misra A., Fourie P.B. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J. Pharm. Sci. 2013, 102:3900-3907.
219. Paranjpe M., Muller-Goymann C.C. Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci. 2014, 15:5852-5873.
220. Shilpi S., Vimal V., Soni V. Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung. Prog. Biomater. 2015, 4:55-63.
221. Lawlor C., Kelly C., O'Leary S., O'Sullivan M.P., Gallagher P.J., Keane J., Cryan S.A. Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb. Tuberculosis (Edinb.) 2011, 91:93-97.
222. Pham D.D., Gregoire N., Couet W., Gueutin C., Fattal E., Tsapis N. Pulmonary delivery of pyrazinamide-loaded large porous particles. Eur. J. Pharm. Biopharm. 2015, 94:241-250.
223. Park T.G. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 1995, 16:1123-1130.
224. Zolnik B.S., Burgess D.J. Effect of acidic pH on PLGA microsphere degradation and release. J. Control. Release 2007, 122:338-344.
225. Perry J.L., Reuter K.G., Kai M.P., Herlihy K.P., Jones S.W., Luft J.C., Napier M., Bear J.E., DeSimone J.M. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012, 12:5304-5310.
226. Healy A.M., Amaro M.I., Paluch K.J., Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv. Drug Deliv. Rev. 2014, 75:32-52.
227. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011, 91:71-81.
228. Prior S., Gander B., Blarer N., Merkle H.P., Subira M.L., Irache J.M., Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 2002, 15:197-207.
229. Torche A.M., Le Corre P., Albina E., Jestin A., Le Verge R. PLGA microspheres phagocytosis by pig alveolar macrophages: influence of poly(vinyl alcohol) concentration, nature of loaded-protein and copolymer nature. J. Drug Target. 2000, 7:343-354.
230. Sosnik A., Seremeta K.P. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv. Colloid Interf. Sci. 2015, 223:40-54.
231. Hirota K., Kawamoto T., Nakajima T., Makino K., Terada H. Distribution and deposition of respirable PLGA microspheres in lung alveoli. Colloids Surf. B: Biointerfaces 2013, 105:92-97.
232. Weiss G., Schaible U.E. Macrophage defense mechanisms against intracellular bacteria. Immunol. Rev. 2015, 264:182-203.
233. Durham P.G., Zhang Y., German N., Mortensen N., Dhillon J., Mitchison D.A., Fourie P.B., Hickey A.J. Spray dried aerosol particles of salts for tuberculosis therapy. Mol. Pharm. 2015, 12:2574-2581.
234. Kwok P.C., Grabarek A., Chow M.Y., Lan Y., Li J.C., Casettari L., Mason A.J., Lam J.K. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Int. J. Pharm. 2015, 491:367-374.
235. Liang W., Kwok P.C., Chow M.Y., Tang P., Mason A.J., Chan H.K., Lam J.K. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur. J. Pharm. Biopharm. 2014, 86:64-73.
236. Ohashi K., Kabasawa T., Ozeki T., Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 2009, 135:19-24.
237. Ungaro F., d'Angelo I., Coletta C., di Villa Bianca R.d.'E., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release 2012, 157:149-159.
238. Lemmer Y., Kalombo L., Pietersen R.D., Jones A.T., Semete-Makokotlela B., Van Wyngaardt S., Ramalapa B., Stoltz A.C., Baker B., Verschoor J.A., Swai H.S., de Chastellier C. Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis. J. Control. Release 2015, 211:94-104.
239. Sharma A., Sharma U. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
240. Ricci M., Giovagnoli S., Blasi P., Schoubben A., Perioli L., Rossi C. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int. J. Pharm. 2006, 311:172-181.
241. Labana S., Pandey R., Sharma S., Khuller G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents 2002, 20:301-304.
242. El-Ridy M.S., Mostafa D.M., Shehab A., Nasr E.A., Abd El-Alim S. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int. J. Pharm. 2007, 330:82-88.
243. Rojanarat W., Nakpheng T., Thawithong E., Yanyium N., Srichana T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv. 2012, 19:334-345.
244. Rojanarat W., Nakpheng T., Thawithong E., Yanyium N., Srichana T. Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 2012, 4:385-412.
245. Pandey R., Sharma S., Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb.) 2005, 85:415-420.
246. Gaspar D.P., Faria V., Goncalves L.M., Taboada P., Remunan-Lopez C., Almeida A.J. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. Int. J. Pharm. 2016, 497:199-209.
247. Song X., Lin Q., Guo L., Fu Y., Han J., Ke H., Sun X., Gong T., Zhang Z. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery. Pharm. Res. 2015, 32:1741-1751.
248. Rose F., Wern J.E., Ingvarsson P.T., van de Weert M., Andersen P., Follmann F., Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: a quality-by-design approach. J. Control. Release 2015, 210:48-57.
249. Bhardwaj A., Mehta S., Yadav S., Singh S.K., Grobler A., Goyal A.K., Mehta A. Pulmonary delivery of antitubercular drugs using spray-dried lipid-polymer hybrid nanoparticles. Artif. Cells Nanomed. Biotechnol. 2015, 1-12.
250. Xie J., Jiang J., Davoodi P., Srinivasan M.P., Wang C.H. Electrohydrodynamic atomization: a two-decade effort to produce and process micro-/nanoparticulate materials. Chem. Eng. Sci. 2015, 125:32-57.
251. Gomez-Mascaraque L.G., Lopez-Rubio A. Protein-based emulsion electrosprayed micro- and submicroparticles for the encapsulation and stabilization of thermosensitive hydrophobic bioactives. J. Colloid Interface Sci. 2016, 465:259-270.
252. Rezvanpour A., Krantz W., Wang C.-H. Scaling analysis of the electrohydrodynamic atomization (EHDA) process for pharmaceutical particle fabrication. Chem. Eng. Sci. 2012, 80:81-90.
253. Tscheka C., Hittinger M., Lehr C.M., Schneider-Daum N., Schneider M. Macrophage uptake of cylindrical microparticles investigated with correlative microscopy. Eur. J. Pharm. Biopharm. 2015, 95:151-155.
254. Roberts R.A., Shen T., Allen I.C., Hasan W., DeSimone J.M., Ting J.P. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One 2013, 8.
255. Watson R.O., Manzanillo P.S., Cox J.S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012, 150:803-815.
256. Zheng H., Lu L., Wang B., Pu S., Zhang X., Zhu G., Shi W., Zhang L., Wang H., Wang S., Zhao G., Zhang Y. Genetic basis of virulence attenuation revealed by comparative genomic analysis of Mycobacterium tuberculosis strain H37Ra versus H37Rv. PLoS One 2008, 3.
257. Frigui W., Bottai D., Majlessi L., Monot M., Josselin E., Brodin P., Garnier T., Gicquel B., Martin C., Leclerc C., Cole S.T., Brosch R. Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog. 2008, 4:e33.
258. Solans L., Aguilo N., Samper S., Pawlik A., Frigui W., Martin C., Brosch R., Gonzalo-Asensio J. A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. Infect. Immun. 2014, 82:3446-3456.
259. Palanisamy G.S., Smith E.E., Shanley C.A., Ordway D.J., Orme I.M., Basaraba R.J. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis 2008, 88:295-306.
260. Srivastava S., Ernst J.D., Desvignes L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol. Rev. 2014, 262:179-192.
261. Hashimoto D., Chow A., Noizat C., Teo P., Beasley M.B., Leboeuf M., Becker C.D., See P., Price J., Lucas D., Greter M., Mortha A., Boyer S.W., Forsberg E.C., Tanaka M., van Rooijen N., Garcia-Sastre A., Stanley E.R., Ginhoux F., Frenette P.S., Merad M. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38:792-804.
262. Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., Hume D.A., Perlman H., Malissen B., Zelzer E., Jung S. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.
263. Sampath D., Castro M., Look D.C., Holtzman M.J. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J. Clin. Invest. 1999, 103:1353-1361.
264. Standiford T.J., Kunkel S.L., Kasahara K., Milia M.J., Rolfe M.W., Strieter R.M. Interleukin-8 gene expression from human alveolar macrophages: the role of adherence. Am. J. Respir. Cell Mol. Biol. 1991, 5:579-585.
265. Tomlinson G.S., Booth H., Petit S.J., Potton E., Towers G.J., Miller R.F., Chain B.M., Noursadeghi M. Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulation. PLoS One 2012, 7.
266. Lawlor C., O'Sullivan M.P., Sivadas N., O'Leary S., Gallagher P.J., Keane J., Cryan S.A. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol. Pharm. 2011, 8:1100-1112.
267. Aston C., Rom W.N., Talbot A.T., Reibman J. Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am. J. Respir. Crit. Care Med. 1998, 157:1943-1950.
268. Samstein M., Schreiber H.A., Leiner I.M., Susac B., Glickman M.S., Pamer E.G. Essential yet limited role for CCR2(+) inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. eLife 2013, 2.
269. Sundaramurthy V., Barsacchi R., Samusik N., Marsico G., Gilleron J., Kalaidzidis I., Meyenhofer F., Bickle M., Kalaidzidis Y., Zerial M. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 2013, 13:129-142.
270. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 1991, 47:22-31.
271. Sharif O., Bolshakov V.N., Raines S., Newham P., Perkins N.D. Transcriptional profiling of the LPS induced NF-kappaB response in macrophages. BMC Immunol. 2007, 8:1.
272. Riendeau C.J., Kornfeld H. THP-1 cell apoptosis in response to Mycobacterial infection. Infect. Immun. 2003, 71:254-259.
273. Dutta N.K., Bruiners N., Pinn M.L., Zimmerman M.D., Prideaux B., Dartois V., Gennaro M.L., Karakousis P.C. Statin adjunctive therapy shortens the duration of TB treatment in mice. J. Antimicrob. Chemother. 2016, 10.1093/jac/dkw014.
274. Chanput W., Mes J.J., Wichers H.J. THP-1 cell line: an in vitro cell model for immune modulation approach. Int. Immunopharmacol. 2014, 23:37-45.
275. Jagannath C., Reddy M.V., Kailasam S., O'Sullivan J.F., Gangadharam P.R. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am. J. Respir. Crit. Care Med. 1995, 151:1083-1086.
276. Jung J.Y., Madan-Lala R., Georgieva M., Rengarajan J., Sohaskey C.D., Bange F.C., Robinson C.M. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. Infect. Immun. 2013, 81:3198-3209.
277. Vogt G., Nathan C. In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J. Clin. Invest. 2011, 121:3889-3901.
278. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., Barnes P.F., Rollinghoff M., Bolcskei P.L., Wagner M., Akira S., Norgard M.V., Belisle J.T., Godowski P.J., Bloom B.R., Modlin R.L. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001, 291:1544-1547.
279. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179:1109-1118.
280. Bodnar K.A., Serbina N.V., Flynn J.L. Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect. Immun. 2001, 69:800-809.
281. Flesch I., Kaufmann S.H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J. Immunol. 1987, 138:4408-4413.
282. Ryan R.C., O'Sullivan M.P., Keane J. Mycobacterium tuberculosis infection induces non-apoptotic cell death of human dendritic cells. BMC Microbiol. 2011, 11:237.
283. Tailleux L., Neyrolles O., Honore-Bouakline S., Perret E., Sanchez F., Abastado J.P., Lagrange P.H., Gluckman J.C., Rosenzwajg M., Herrmann J.L. Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J. Immunol. 2003, 170:1939-1948.
284. Randall P.J., Hsu N.J., Quesniaux V., Ryffel B., Jacobs M. Mycobacterium tuberculosis infection of the 'non-classical immune cell'. Immunol. Cell Biol. 2015, 93:789-795.
285. Ong C.W., Elkington P.T., Friedland J.S. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 2014, 190:9-18.
286. Elkington P.T., Green J.A., Emerson J.E., Lopez-Pascua L.D., Boyle J.J., O'Kane C.M., Friedland J.S. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am. J. Respir. Cell Mol. Biol. 2007, 37:431-437.
287. Walker N.F., Clark S.O., Oni T., Andreu N., Tezera L., Singh S., Saraiva L., Pedersen B., Kelly D.L., Tree J.A., D'Armiento J.M., Meintjes G., Mauri F.A., Williams A., Wilkinson R.J., Friedland J.S., Elkington P.T. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 2012, 185:989-997.
288. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., Wilkinson K.A., Banchereau R., Skinner J., Wilkinson R.J., Quinn C., Blankenship D., Dhawan R., Cush J.J., Mejias A., Ramilo O., Kon O.M., Pascual V., Banchereau J., Chaussabel D., O'Garra A. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
289. Lowe D.M., Redford P.S., Wilkinson R.J., O'Garra A., Martineau A.R. Neutrophils in tuberculosis: friend or foe?. Trends Immunol. 2012, 33:14-25.
290. Ong C.W., Elkington P.T., Brilha S., Ugarte-Gil C., Tome-Esteban M.T., Tezera L.B., Pabisiak P.J., Moores R.C., Sathyamoorthy T., Patel V., Gilman R.H., Porter J.C., Friedland J.S. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog. 2015, 11.
291. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., Cho S.N., Via L.E., Barry C.E. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137:122-128.
292. Nathan C., Barry C.E. TB drug development: immunology at the table. Immunol. Rev. 2015, 264:308-318.
293. Fitzgerald L.E., Abendano N., Juste R.A., Alonso-Hearn M. Three-dimensional in vitro models of granuloma to study bacteria-host interactions, drug-susceptibility, and resuscitation of dormant mycobacteria. Biomed. Res. Int. 2014, 2014:623856.
294. Puissegur M.P., Botanch C., Duteyrat J.L., Delsol G., Caratero C., Altare F. An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell. Microbiol. 2004, 6:423-433.
295. Guirado E., Mbawuike U., Keiser T.L., Arcos J., Azad A.K., Wang S.H., Schlesinger L.S. Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model. mBio 2015, 6. (e02537-02514).
296. Silva-Miranda M., Ekaza E., Breiman A., Asehnoune K., Barros-Aguirre D., Pethe K., Ewann F., Brodin P., Ballell-Pages L., Altare F. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2015, 59:693-697.
297. Parasa V.R., Rahman M.J., Ngyuen Hoang A.T., Svensson M., Brighenti S., Lerm M. Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue. Dis. Model. Mech. 2014, 7:281-288.
298. Franzblau S.G., DeGroote M.A., Cho S.H., Andries K., Nuermberger E., Orme I.M., Mdluli K., Angulo-Barturen I., Dick T., Dartois V., Lenaerts A.J. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2012, 92:453-488.
299. Hanif S.N., Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front. Cell Infect. Microbiol. 2012, 2:118.
300. Cryan S.A., Sivadas N., Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv. Drug Deliv. Rev. 2007, 59:1133-1151.
301. Kramnik I., Beamer G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin. Immunopathol. 2016, 38(2):221-237.
302. Driver E.R., Ryan G.J., Hoff D.R., Irwin S.M., Basaraba R.J., Kramnik I., Lenaerts A.J. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56:3181-3195.
303. Gupta S., Tyagi S., Almeida D.V., Maiga M.C., Ammerman N.C., Bishai W.R. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 2013, 188:600-607.
304. Skerry C., Pinn M.L., Bruiners N., Pine R., Gennaro M.L., Karakousis P.C. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. 2014, 69:2453-2457.
305. Reeme A.E., Robinson R.T. Dietary vitamin D3 suppresses pulmonary immunopathology associated with late-stage tuberculosis in C3HeB/FeJ mice. J. Immunol. 2016, 196:1293-1304.
306. Guirado E., Schlesinger L.S. Modeling the Mycobacterium tuberculosis granuloma-the critical battlefield in host immunity and disease. Front. Immunol. 2013, 4:98.
307. Flynn J.L., Gideon H.P., Mattila J.T., Lin P.L. Immunology studies in non-human primate models of tuberculosis. Immunol. Rev. 2015, 264:60-73.